Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab′)2: A long-term study of renal function in nude mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 6, 2009, Pages 649-658

  Bäck, Tom ^a   Haraldsson, Börje ^b   Hultborn, Ragnar ^a   Jensen, Holger ^c   Johansson, Martin E ^d   Lindegren, Sture ^a   Jacobsson, Lars ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Rigshospitalet   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Astatine 211; Glomerular filtration rate; Radioimmunotherapy; Renal function

Indexed keywords

ASTATINE; EDETATE CHROMIUM CR 51; MONOCLONAL ANTIBODY; MX35 FAB 2 MONOCLONAL ANTIBODY AT 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE MARROW; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; KIDNEY FUNCTION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RADIOIMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MICE; MICE, NUDE; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; RADIOIMMUNODETECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 73649129602     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0628     Document Type: Article

References (31)

1. Andersson H, Elgqvist J, Horvath G, et al. Astatine-211- labeled antibodies for treatment of disseminated ovarian cancer: An overview of results in an ovarian tumor model. Clin Cancer Res 2003;9(10 Pt 2):3914S.
2. Elgqvist J, Andersson H, Back T, et al. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J Nucl Med 2005;46:1907.
3. Hultborn RA. Pharmacokinetics and dosimetry of 211At- MX35 F(ab0)2 in therapy of ovarian cancer-preliminary results from an ongoing Phase I study. Cancer Biother Radiopharm 2006;21:373.
4. Casey JL, King DJ, Chaplin LC, et al. Preparation, characterisation, and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab0 fragments. Br J Cancer 1996; 74:1397.
5. Casey JL, Pedley RB, King DJ, et al. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab0 fragments. Br J Cancer 1999;81:972.
6. Flynn AA, Pedley RB, Green AJ, et al. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res 2003;159:182.
7. King DJ, Turner A, Farnsworth AP, et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994;54:6176.
8. Nadasdy T, Laszik Z, Blick KE, et al. Proliferative activity of intrinsic cell populations in the normal human kidney. J Am Soc Nephrol 1994;4:2032.
9. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001; 28:1552.
10. Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)- octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46 (suppl1):83S.
11. Konijnenberg M, Melis M, Valkema R, et al. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007;48:134.
12. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD Pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med 2008;49:1184.
13. Bouchet LG, Bolch WE, Blanco HP, et al. MIRD Pamphlet No 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 2003;44:1113.
14. Bäck T. The Alpha Camera: Evaluation of a new CCD-based digital autoradiography technique for high resolution exvivo bioimaging. Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates. Cancer Biother Radiopharm 2008;23:513.
15. Lindegren S, Back T, Jensen HJ. Dry-distillation of astatine- 211 from irradiated bismuth targets: A time-saving procedure with high recovery yields. Appl Radiat Isot 2001; 55:157.
16. Lindegren S, Andersson H, Back T, et al. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl) benzoate. Nucl Med Biol 2001;28:33.
17. Welshinger M, Yin BW, Lloyd KO. Initial immunochemical characterization of MX35 ovarian cancer antigen. Gynecol Oncol 1997;67:188.
18. Yin BW, Kiyamova R, Chua R, et al. Monoclonal antibody MX35 detects the membrane transporter, NaPi2b (SLC34A2), in human carcinomas. Cancer Immun 2008;8:3.
19. Back T, Andersson H, Divgi CR, et al. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an alphaemitter in vivo. J Nucl Med Dec 2005;46(12):2061-2067.
20. Elgqvist J, Bernhardt P, Hultborn R, et al. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. J Nucl Med 2005;46:464.
21. Zalutsky MR. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. J Nucl Med 2006;47:1238.
22. Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008; 49:30.
23. Maack T, Park CH, Camargo MJF. Renal filtration, transport, and metabolism of proteins. In: Seldin DW, Giebisch G, eds. The Kidney 3rd ed. New York: Raven Press, 2000;2235-2267.
24. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008;88:451.
25. Mattes MJ, Look K, Furukawa K, et al. Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells. Cancer Res 1987;47(24 Pt 1):6741.
26. Altunkaynak ME, Ozbek E, Altunkaynak BZ, et al. The effects of high-fat diet on the renal structure and morphometric parametric of kidneys in rats. J Anat 2008;212:845.
27. Jaggi JS, Seshan SV, McDevitt MR, et al. Renal tubulointerstitial changes after internal irradiation with alpha-particleemitting actinium daughters. J Am Soc Nephrol 2005;16: 2677.
28. Robinson MK, Shaller C, Garmestani K, et al. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alphaemitting radioisotope astatine-211 conjugated to anti-HER2= neu diabodies. Clin Cancer Res 2008;14:875.
29. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109.
30. Williams MV, Denekamp J. Sequential functional testing of radiation-induced renal damage in the mouse. Radiat Res 1983;94:305.
31. Elgqvist J, Andersson H, Back T, et al. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab0)2: Therapeutic efficacy and myelotoxicity. Nucl Med Biol 2006;33: 1065.